Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Buy
67
LPCN Quote, Financials, Valuation and Earnings
Last price:
$3.11
Seasonality move
:
-5.53%
Day range:
$2.98 - $3.15
52-week range:
$2.52 - $5.50
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
3.85x
P/B ratio:
1.22x
Volume:
16.7K
Avg. volume:
45.9K
1-year change:
-36.86%
Market cap:
$17.2M
Revenue:
$11.2M
EPS (TTM):
-$1.02
Analysts' Opinion
-
Consensus RatingLipocine, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $6.88, Lipocine, Inc. has an estimated upside of 121.77% from its current price of $3.10.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $6.75 representing 100% downside risk from its current price of $3.10.
Fair Value
-
According to the consensus of 2 analysts, Lipocine, Inc. has 121.77% upside to fair value with a price target of $6.88 per share.
LPCN vs. S&P 500
-
Over the past 5 trading days, Lipocine, Inc. has underperformed the S&P 500 by -5.6% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Lipocine, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Lipocine, Inc. has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Lipocine, Inc. reported revenues of $114.6K.
Earnings Growth
-
Lipocine, Inc. earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Lipocine, Inc. reported earnings per share of -$0.59.
Enterprise value:
2.1M
EV / Invested capital:
0.15x
Price / LTM sales:
3.85x
EV / EBIT:
--
EV / Revenue:
0.48x
PEG ratio (5yr expected):
-0.09x
EV / Free cash flow:
-0.40x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$4.3M
Return On Assets:
-27.83%
Net Income Margin (TTM):
-126.66%
Return On Equity:
-30.22%
Return On Invested Capital:
-30.22%
Operating Margin:
-2932.81%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $55K | $7.8M | $4.3M | -- | $114.6K | |
| Gross Profit | $31.8K | $7.7M | $4.3M | -$8.5K | $100.5K | |
| Operating Income | -$14.8M | -$5.5M | -$6.3M | -$2.6M | -$3.4M | |
| EBITDA | -$14.8M | -$5.4M | -$6.2M | -$2.6M | -$3.3M | |
| Diluted EPS | -$3.14 | -$0.76 | -$1.02 | -$0.41 | -$0.59 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $40.4M | $36.1M | $24.6M | $20.5M | $15.9M | |
| Total Assets | $40.4M | $39.4M | $24.8M | $20.7M | $16.1M | |
| Current Liabilities | $6.4M | $1.5M | $2.2M | $1.6M | $1.9M | |
| Total Liabilities | $7.6M | $1.8M | $2.3M | $1.6M | $1.9M | |
| Total Equity | $32.8M | $37.6M | $22.5M | $19.1M | $14.1M | |
| Total Debt | $3.1M | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$11.7M | -$4.9M | -$5.1M | -$2.8M | -$3M | |
| Cash From Investing | $13M | $4.4M | $5.1M | $1M | $701.4K | |
| Cash From Financing | $404K | $204K | $217K | -- | $141.3K | |
| Free Cash Flow | -$11.8M | -$5M | -$5.1M | -$2.9M | -$3M | |
LPCN
Sector
Market Cap
$17.2M
$28.4M
Price % of 52-Week High
56.36%
50.35%
Dividend Yield
0%
0%
Shareholder Yield
-1.4%
-1.32%
1-Year Price Total Return
-36.86%
-22.19%
Beta (5-Year)
1.027
0.521
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$3.25
200-day SMA
Sell
Level
$3.14
Bollinger Bands (100)
Buy
Level
2.8 - 3.22
Chaikin Money Flow
Sell
Level
-206.9K
20-day SMA
Buy
Level
$3.07
Relative Strength Index (RSI14)
Buy
Level
51.28
ADX Line
Buy
Level
37.81
Williams %R
Neutral
Level
-62.8205
50-day SMA
Buy
Level
$2.98
MACD (12, 26)
Buy
Level
0.18
25-day Aroon Oscillator
Buy
Level
40
On Balance Volume
Neutral
Level
181.5K
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-0.6368)
Buy
CA Score
(Annual)
Level (1.3765)
Sell
Beneish M-Score
(Annual)
Level (86.9417)
Sell
Momentum Score
Level (2)
Buy
Ohlson Score
Level (-1016.5218)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (6)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Lipocine, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of the delivery of drugs using proprietary delivery technology. It offers TLANDO, an oral testosterone replacement therapy. The company was founded on October 13, 2011 and is headquartered in Salt Lake City, UT.
Stock Forecast FAQ
In the current month, LPCN has received 2 Buy ratings 0 Hold ratings, and 0 Sell ratings. The LPCN average analyst price target in the past 3 months is $6.88.
-
Where Will Lipocine, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Lipocine, Inc. share price will rise to $6.88 per share over the next 12 months.
-
What Do Analysts Say About Lipocine, Inc.?
Analysts are divided on their view about Lipocine, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Lipocine, Inc. is a Sell and believe this share price will drop from its current level to $6.75.
-
What Is Lipocine, Inc.'s Price Target?
The price target for Lipocine, Inc. over the next 1-year time period is forecast to be $6.88 according to 2 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is LPCN A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Lipocine, Inc. is a Buy. 2 of 2 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of LPCN?
You can purchase shares of Lipocine, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Lipocine, Inc. shares.
-
What Is The Lipocine, Inc. Share Price Today?
Lipocine, Inc. was last trading at $3.11 per share. This represents the most recent stock quote for Lipocine, Inc.. Yesterday, Lipocine, Inc. closed at $3.10 per share.
-
How To Buy Lipocine, Inc. Stock Online?
In order to purchase Lipocine, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get LPCN Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
LPCN
Sector
P/E ratio
--
23.66x
PEG ratio
-0.09x
-0.01x
P/B ratio
1.22x
1.84x
Price / LTM sales
3.85x
1.60x
Growth Metrics
LPCN
Sector
Revenue growth
595.42%
4.85%
Earnings growth
-41.89%
11.15%
Revenue (5-year growth)
132.45%
6.45%
Earnings forecast
--
-$0.20
Profitability
LPCN
Sector
Profitability FY 2024
$11.2M
$3.6M
Return on invested capital
-30.22%
-30.98%
Return on assets
-27.83%
-27.62%
Return on equity
-30.22%
-36.69%
Earnings Date
Last Earnings Date
Aug
14
Next Earnings Date
Dec
5
Estimated Next Earnings Date
Mar
6
Balance Sheet
LPCN
Sector
Total cash
$15.1M
$27.2M
Short term investments
$15.4M
$25.7M
Total assets
$22.5M
$79.9M
Long term debt
--
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 62x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
63
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 40x
Alerts
Buy
54
SMX alert for Dec 5
SMX (Security Matters) Plc [SMX] is up 154.74% over the past day.
Sell
15
HOV alert for Dec 5
Hovnanian Enterprises, Inc. [HOV] is down 22.58% over the past day.
Buy
67
NUTX alert for Dec 5
Nutex Health, Inc. [NUTX] is up 18.9% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
